November 29, 2016 - By Adrian Mccoy · 0 Comments
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) institutional sentiment decreased to 0.81 in Q2 2016. Its down -0.44, from 1.25 in 2016Q1. The ratio turned negative, as 181 investment managers increased and started new stock positions, while 145 trimmed and sold stock positions in Jazz Pharmaceuticals PLC. The investment managers in our partner’s database reported: 52.76 million shares, down from 53.73 million shares in 2016Q1. Also, the number of investment managers holding Jazz Pharmaceuticals PLC in their top 10 stock positions increased from 10 to 11 for an increase of 1. Sold All: 43 Reduced: 102 Increased: 120 New Position: 61.
About 34,791 shares traded hands. Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) has declined 30.14% since April 26, 2016 and is downtrending. It has underperformed by 35.40% the S&P500.
Analysts await Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) to report earnings on February, 28. They expect $1.67 earnings per share, down 26.43% or $0.60 from last year’s $2.27 per share. JAZZ’s profit will be $100.95M for 16.02 P/E if the $1.67 EPS becomes a reality. After $2.16 actual earnings per share reported by Jazz Pharmaceuticals plc – Ordinary Shares for the previous quarter, Wall Street now forecasts -22.69% negative EPS growth.
According to Zacks Investment Research, “Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. Company’s goal is to build a broad portfolio of products through a combination of internal development and acquisition/in-licensing activities and to utilize our specialty sales force to promote products in our target markets. They apply novel formulations and drug delivery technologies to known drug compounds, and compounds with the same mechanism of action or similar chemical structure as marketed products, to improve patient care by improving efficacy, reducing adverse side effects or increasing patient compliance relative to existing therapies. Based in Palo Alto, California, the company is committed to working closely with patients, patient advocacy groups and healthcare professionals.”
Pine River Capital Management L.P. holds 42.31% of its portfolio in Jazz Pharmaceuticals plc – Ordinary Shares for 12,520 shares. Cadian Capital Management Lp owns 764,236 shares or 5.93% of their US portfolio. Moreover, Ardsley Advisory Partners has 4.62% invested in the company for 188,500 shares. The Colorado-based Rk Capital Management Llc has invested 4.02% in the stock. Magee Thomson Investment Partners Llc, a California-based fund reported 71,300 shares.#img1#
Insider Transactions: Since January 1, 0001, the stock had 4 insider buys, and 16 sales for $4.67 million net activity.
Ratings analysis reveals 85% of Jazz Pharmaceuticals’s analysts are positive. Out of 13 Wall Street analysts rating Jazz Pharmaceuticals, 11 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. The lowest target is $124 while the high is $229. The stock’s average target of $182.27 is 70.30% above today’s ($107.03) share price. JAZZ was included in 21 notes of analysts from August 3, 2015. The firm has “Buy” rating by Mizuho given on Wednesday, May 11. The firm has “Buy” rating by Stifel Nicolaus given on Wednesday, February 24. Northland Capital initiated Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) rating on Wednesday, October 14. Northland Capital has “Outperform” rating and $200 price target. The company was maintained on Wednesday, May 11 by UBS. The firm has “Buy” rating by Deutsche Bank given on Thursday, August 11. The firm has “Market Perform” rating given on Wednesday, November 25 by Bernstein. Wells Fargo initiated Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) on Friday, February 19 with “Outperform” rating. Mizuho maintained it with “Buy” rating and $127 target price in Wednesday, November 9 report. The company was initiated on Wednesday, June 29 by BMO Capital Markets. The firm has “Neutral” rating given on Tuesday, November 10 by Mizuho.
Jazz Pharmaceuticals Public Limited Company, incorporated on March 15, 2005, is a biopharmaceutical company. The Firm is focused on developing and commercializing products that address unmet medical needs. The Firm has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. The Company’s lead marketed products include Xyrem (sodium oxybate oral solution) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze for the treatment of acute lymphoblastic leukemia (ALL), and Defitelio (defibrotide) for the treatment of severe hepatic veno-occlusive disease (VOD). The Company’s other product candidates include JZP-110 for treatment of excessive daytime sleepiness (EDS) in narcolepsy and EDS in patients with obstructive sleep apnea (OSA) and JZP-386 for the treatment of EDS in narcolepsy.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Adrian Mccoy
Tags: Ordinary Shares